Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 18/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 18/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20721509 | 0.85 | PRMT5 (0.46) | PRMT5WDR77 | |
| SCHEMBL29391779 | 0.82 | PRMT5 (0.55) | PRMT5WDR77 | |
| SCHEMBL20733632 | 0.77 | PRMT5 (0.51) | PRMT5WDR77 | |
| SCHEMBL18571696 | 0.77 | PI4KA (0.47) | PRMT5WDR77 | |
| SCHEMBL18571700 | 0.77 | PI4KA (0.47) | PRMT5WDR77 | |
| SCHEMBL25949203 | 0.77 | PI4KA (0.47) | PRMT5WDR77 | |
| SCHEMBL22522087 | 0.76 | PRMT5 (0.50) | PRMT5WDR77 | |
| SCHEMBL22002162 | 0.76 | PRMT5 (0.37) | PRMT5WDR77PDPK1 | |
| SCHEMBL22002064 | 0.75 | PRMT5 (0.35) | PRMT5WDR77PDPK1 | |
| SCHEMBL20049564 | 0.71 | PDPK1 (0.34) | PRMT5WDR77PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| EP-3952874-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | Prelude Therapeutics, Incorporated (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 76/4885PDPK1 1840/4885 |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 283/4885PDPK1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.